Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Mario Malerba, Alessandro Radaeli, Giuseppe Santini, Jaymin Morjaria, Nadia Mores, Chiara Mondino, Giuseppe Macis & Paolo Montuschi. (2018) The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Discovery 13:6, pages 563-577.
Read now
Read now
Jose Luis Lopez-Campos, Carmen Calero, Cecilia Lopez-Ramirez, Maria Isabel Asensio-Cruz, Eduardo Márquez-Martín & Francisco Ortega-Ruiz. (2015) Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium. Patient Preference and Adherence 9, pages 95-104.
Read now
Read now
Subhabrata Moitra, Arvind B Bhome & Bill B Brashier. (2015) Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date. Drug Design, Development and Therapy 9, pages 1989-1999.
Read now
Read now
Charlotte Suppli Ulrik. (2015) Once-daily glycopyrronium bromide (Seebri Breezhaler®) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 16:17, pages 2653-2659.
Read now
Read now
Debra J Reid & Alexa A Carlson. (2014) Clinical use of aclidinium in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 9, pages 369-379.
Read now
Read now
Emily M. Armstrong, Bradley M. Wright, Allison Meyer, Courtney S. Watts & Kristi W. Kelley. (2014) The Role of Aclidinium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease. Hospital Practice 42:4, pages 99-110.
Read now
Read now
Jose Luis Lopez-Campos, Carmen Calero & Esther Quintana-Gallego. (2013) Symptom variability in COPD: a narrative review. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 231-238.
Read now
Read now
Mario Cazzola, Clive P Page & Maria Gabriella Matera. (2013)
Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy 14:9, pages 1205-1214.
Read now
Read now
Vandana Gupta & Dave Singh. (2012) Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 6:6, pages 581-588.
Read now
Read now
Charlotte Suppli Ulrik. (2012) Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 673-678.
Read now
Read now
Michael W Sims & Reynold A Panettieri$suffix/text()$suffix/text(). (2011) Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 457-466.
Read now
Read now
Articles from other publishers (14)
Dean Quinn, Christopher N. Barnes, Wayne Yates, David L. Bourdet, Edmund J. Moran, Peter Potgieter, Andrew Nicholls, Brett Haumann & Dave Singh. (2018) Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulmonary Pharmacology & Therapeutics 48, pages 71-79.
Crossref
Crossref
Paola Rogliani, Luigino Calzetta, Josuel Ora, Roberto Lipsi, Andrea Segreti, Maria Gabriella Matera & Mario Cazzola. (2015) Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. European Journal of Pharmacology 761, pages 383-390.
Crossref
Crossref
Han Ni, Zay Soe & Soe Moe. (2014) Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2015:4.
Crossref
Crossref
L. E. Stone, J. W. Skelley, J. A. Kyle & L. K. Elmore. (2014) Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 71:5, pages 386-393.
Crossref
Crossref
Khuder Alagha, Alain Palot, Tunde Sofalvi, Laurie Pahus, Marion Gouitaa, Celine Tummino, Stephanie Martinez, Denis Charpin, Arnaud Bourdin & Pascal Chanez. (2014) Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Therapeutic Advances in Chronic Disease 5:2, pages 85-98.
Crossref
Crossref
Alexander G. Mathioudakis, Victoria Chatzimavridou-Grigoriadou & Georgios A. Mathioudakis. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
241
256
.
Anthony D’Urzo. (2013) Optimizing the management of chronic obstructive pulmonary disease: applying the GOLD strategy. Clinical Practice 10:4, pages 481-492.
Crossref
Crossref
J Andrew Woods, Kimberly L Nealy & Robert W Barrons. (2013) Aclidinium Bromide: An Alternative Long-Acting Inhaled Anticholinergic in the Management of Chronic Obstructive Pulmonary Disease. Annals of Pharmacotherapy 47:7-8, pages 1017-1028.
Crossref
Crossref
Donald P Tashkin & Gary T Ferguson. (2013) Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respiratory Research 14:1, pages 49.
Crossref
Crossref
Nicolas Roche, Niels H Chavannes & Marc Miravitlles. (2013) COPD symptoms in the morning: impact, evaluation and management. Respiratory Research 14:1, pages 112.
Crossref
Crossref
James E. Frampton. (2012) Aclidinium. Drugs 72:15, pages 1999-2011.
Crossref
Crossref
Mario Cazzola, Clive P. Page, Luigino Calzetta & M. Gabriella Matera. (2012) Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews 64:3, pages 450-504.
Crossref
Crossref
H. Chrystyn & C. Niederlaender. (2012) The Genuair® inhaler: a novel, multidose dry powder inhaler. International Journal of Clinical Practice 66:3, pages 309-317.
Crossref
Crossref
Jakob Busch-PetersenDramane I Lainé. (2011) Inhaled long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Future Medicinal Chemistry 3:13, pages 1623-1634.
Crossref
Crossref